Novavax (NVAX) EBT (2010 - 2026)

Novavax's EBT history runs 17 years deep, the most recent figure standing at -$8.5 million for Q1 2026.

• In Q1 2026, EBT fell 101.64% year-over-year to -$8.5 million; the TTM figure through Mar 2026 stood at -$86.2 million (down 117.64% YoY), while the FY2025 annual figure was $442.2 million, up 350.36% from the prior year.
• EBT was -$8.5 million for Q1 2026 at Novavax, down from $17.9 million in the prior quarter.
• In the past five years, EBT ranged from a high of $519.8 million in Q1 2025 to a low of -$509.1 million in Q2 2022.
• Historically, EBT has averaged -$55.3 million across 5 years, with a median of -$122.3 million in 2024.
• The sharpest annual moves came in 2023 and 2025: EBT tumbled 242.05% in 2023, then soared 457.8% in 2025.
• A 5-year view of EBT shows it stood at -$184.5 million in 2022, then advanced by 4.23% to -$176.7 million in 2023, then soared by 58.36% to -$73.6 million in 2024, then soared by 124.33% to $17.9 million in 2025, then sank by 147.51% to -$8.5 million in 2026.
• The last three EBT figures came in at -$8.5 million (Q1 2026), $17.9 million (Q4 2025), and -$203.0 million (Q3 2025), per Business Quant data.